An analysis using mixed quantitative and qualitative methods, as well as site visits to 7 US oncology practices, identified 13 attributes within 5 themes that potentially contribute to high-quality care at a relatively low total cost.
An analysis of positive deviant oncology care pinpointed the themes and attributes that likely contribute to high-value cancer care.
“Cancer care is complex, variably delivered, and usually conducted in an ambulatory setting by physician-led teams,” wrote the authors of the analysis, published in JAMA Oncology. “The complexity and variation in care delivery creates opportunities to identify attributes of ambulatory oncology practices that deliver high-value care, that is high-quality care at a relatively low total cost.”
The authors began their exploratory hypothesis-generating study with quantitative methods to identify positive deviant practices, or practices that ranked favorably compared with their peers on low mean total spending per treatment episode, and also scored highly on ambulatory quality measures. They then applied qualitative methods to identify potentially transferrable attributes of high-value care.
Value was quantified from high-quality oncology practices located near the US Pacific Northwest and Midwest with low mean insurer-allowed spending. Four positive deviant oncology practices and 3 oncology practices that ranked near the middle of the spending distribution were studied.
Two-day site visits were conducted between June 2, 2015 and October 3, 2015 to interview personnel and identify attributes of high-value care. Questions focused on care delivery methods, staff roles and functions, patient services provided, cultural norms, and diagnostic and surveillance testing used. A qualitative analysis was then performed to pinpoint attributes occurring uniquely or frequently in the practices.
The authors identified 13 distinct attributes that potentially affect care cost and quality:
The attributes were grouped into 5 themes: Treatment planning and goal setting; support for the patient journey; care team organized so that members function at the highest level allowed by their competence and license; technical support and physical layout; and external context.
“Organizations facing increased pressure to lower healthcare spending and improve quality of oncology care can view this study as an additional source of insight, until readily transferable attributes of care are tested and available to inform more refined system designs,” concluded the authors.
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More